Skip to main content
. 2024 Mar 5;17(3):e13727. doi: 10.1111/cts.13727

FIGURE 1.

FIGURE 1

Analysis populations. M, moxifloxacin (400 mg); P, placebo (4 rimegepant‐matching placebo tablets); PK, pharmacokinetic; QTc, corrected QT interval; ST, rimegepant supratherapeutic dose (300 mg; 4 × 75 mg rimegepant tablets); T, rimegepant therapeutic dose (75 mg; 1 × 75 mg rimegepant tablet and 3 matching placebo tablets).